证券之星消息，根据市场公开信息及8月25日披露的机构调研信息，长信基金近期对4家上市公司进行了调研，相关名单如下： 1）稳健医疗 （长信基金参与公司业绩说明会&线上调研） 调研纪要：全棉时代第二季度实现13%同比增长，7-8月销售增速回升，坚持四大战略推动业务发展。医疗板块成长空间大，将围绕三大战略展 开，重点提升产品结构和生产效率，推进海外供应链建设。棉柔巾业务增长持续好于大盘，下半年将推出多款新品，加强渠道建设。GRI上半年 受中美关税战影响，但供应链已全面恢复，预计下半年趋势向好。高端敷料、手术室耗材、健康个护业务增速较高，传统敷料业务保持稳定。全 棉时代上半年毛利率提升，下半年将继续优化商品组合和渠道结构，提升利润率。线下门店将聚焦高质量开店，提升同店同比，优化会员服务。 所得税率上升主要因业务结构变化和全棉时代子公司迁址导致。 2）兆易创新 调研纪要：兆易创新在2024年二季度各业务线增长情况良好，NOR Flash高个位数增长，利基型DRAM增长超50%，MCU接近20%，模拟芯片基数 低环比成长较高，传感器芯片增长约10%。预计第三季度环比增长，全年需求上涨，利基型DRAM供应偏紧缺至全年。下半 ...

证券代码：300888 证券简称：稳健医疗 稳健医疗用品股份有限公司投资者关系活动记录表 编号：2025-006 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活 | □媒体采访 √业绩说明会 | | 动类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 （电话会议） | | 参与单位名称 | 交银施罗德基金、嘉实基金、信达澳亚基金等 139 位机构投资者，名单详见 | | 及人员姓名 | 附件（排名不分先后） | | 时间 | 年 月 日 2025 8 22 | | 地点 | 公司总部会议室 | | | 方修元：董事、首席财务官 | | 上市公司接待 | 吴克震：监事、医疗板块轮值 CEO | | 人员姓名 | 廖美珍：董事、全棉时代高级副总裁 | | | 陈惠选：副总经理、董事会秘书 | | | 介绍内容详见附件业绩推介材料，问答记录如下： | | 1. | 请问公司如何看待全棉时代近期恢复情况，并请分享一下消费品业务下 | | | 半年展望以及未来 1-2 年的核心增长动力。 | | | 答：首先，全棉时代第二季度实现 13%同比增长，公 ...

朝闻国盛 杰克逊霍尔：不止放鸽，还有政策框架修订 今日概览 证券研究报告 | 朝闻国盛 gszqdatemark 2025 08 25 年 月 日 【宏观】高频半月观—8 月以来出口表现仍强——20250824 【宏观】杰克逊霍尔：不止放鸽，还有政策框架修订——20250823 重磅研报 【固定收益】资金宽松，杠杆下降——流动性和机构行为跟踪—— 20250823 【银行】2025上半年各地信贷增速及贷款利率有何变化？——20250824 【电子】消费电子进入新品发布旺季，板块估值重塑可期——20250824 【建筑】联检科技（301115.SZ）-并购拓疆步入收获期，检测龙头迎新 增长拐点——20250824 【食品饮料】安琪酵母（600298.SH）-以史为鉴，大周期起点 —— 20250824 【金融工程】食品饮料终于迎来日线级别上涨——20250824 【金融工程】择时雷达六面图：本周估值分数继续下行——20250823 【固定收益】债对股的敏感性或下降——20250824 【固定收益】化债见成果——各地 2025 年 H1 经济财政债务盘点—— 20250823 【电力设备】威力传动（300904. ...

稳健医疗 20250822 摘要 稳健医疗上半年营收 25 亿元，同比增长 46%，剔除并购公司 Gri 影响 后增长 13.2%。全棉时代营收 27.5 亿元，同比增长 20%，消费品板块 增长显著，但二季度受 315 事件影响增速放缓。 公司销售费用率因 Gri 公司 ToB 业务占比提升而下降，管理费用率因 Gri 公司管理费用较高而上升，但剔除 Gri 影响后均与去年同期持平。研 发投入持续加大，取得多项专利和医疗产品注册证。 全棉时代加强科技创新，在九大科技领域取得突破，重点推进零添加棉 柔巾和超净洗卫生巾等产品。奈斯公主卫生巾增长 68%，棉柔巾增长 19%，线上渠道增长 23.6%，抖音平台增长 100%。 公司坚持产品领先、卓越运营、品牌向上和全球视野四大战略。聚焦棉 柔巾、卫生巾、贴身衣物及婴童服饰等核心产品，推进门店经营精细化， 加强品牌建设，拓展海外市场。 医疗板块表现优异，营业利润率提升至 8.6%，消费品业务营业利润率 提升至 14%，整体毛利率提升至 58.6%。通过优化生产流程、增强品 牌影响力、推广创新产品和加强全球供应链管理，支持中长期成长目标。 Q&A 稳健医疗在 2025 ...

据证券之星公开数据整理，近期稳健医疗（300888）发布2025年中报。截至本报告期末，公司营业总收 入52.96亿元，同比上升31.31%，归母净利润4.92亿元，同比上升28.07%。按单季度数据看，第二季度 营业总收入26.91亿元，同比上升26.66%，第二季度归母净利润2.43亿元，同比上升20.68%。本报告期 稳健医疗公司应收账款体量较大，当期应收账款占最新年报归母净利润比达173.23%。 本次财报公布的各项数据指标表现尚佳。其中，毛利率48.33%，同比减0.79%，净利率9.78%，同比减 2.85%，销售费用、管理费用、财务费用总计16.8亿元，三费占营收比31.72%，同比减3.65%，每股净资 产19.79元，同比增1.84%，每股经营性现金流0.58元，同比增77.62%，每股收益0.84元，同比增28.64% | | | | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 40.34亿 | 52.96725 | 31.31% | | 归母净利润(元) | 3.84Z | 4.92亿 | ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [3][6]. Core Insights - The company reported a strong performance in H1 2025, achieving revenue of 5.3 billion yuan, a year-on-year increase of 31.3%, and a net profit attributable to shareholders of 490 million yuan, up 28.1% year-on-year [5][6]. - The medical segment showed robust growth, with revenue of 2.52 billion yuan in H1, a year-on-year increase of 46.4%. Excluding the newly acquired GRI, the medical segment's revenue was 1.95 billion yuan, up 13.2% year-on-year [5][6]. - The consumer goods segment also performed well, with revenue of 2.75 billion yuan in H1, a year-on-year increase of 20.3%. The core product categories, such as sanitary napkins, saw significant growth, with revenue increasing by 67.6% [5][6]. Financial Performance Summary - H1 2025 revenue breakdown: - Medical segment: 2.52 billion yuan, up 46.4% year-on-year - Consumer goods segment: 2.75 billion yuan, up 20.3% year-on-year - H1 2025 net profit: 490 million yuan, up 28.1% year-on-year - H1 2025 gross margin: 48.3%, down 0.4 percentage points year-on-year [5][6]. Earnings Forecast and Investment Recommendations - The company plans to distribute a mid-term dividend of 260 million yuan, with a payout ratio of 53% [5][6]. - Forecasted net profits for 2025-2027 are 1 billion yuan, 1.21 billion yuan, and 1.45 billion yuan, with growth rates of 43.8%, 21.0%, and 19.7% respectively [5][6].

本报记者李昱丞 8月21日晚间，稳健医疗用品股份有限公司（以下简称"稳健医疗"）披露2025年半年度报告。报告显 示，公司2025年上半年实现营业收入52.96亿元，同比增长31.31%；实现归母净利润4.92亿元，同比增 长28.07%；实现扣非后归母净利润4.61亿元，同比增长40.90%。 （文章来源：证券日报） 就渠道而言，2025年全棉时代线上渠道实现收入17.1亿元，同比增长23.6%。截至2025年上半年末，线 下门店达484家，全域会员人数近6700万，较2024年年末增长7.7%。 除此以外，上半年稳健医疗盈利能力持续优化，两大业务营业利润率双升。 半年报显示，受益于产品结构优化与原材料棉花价格下行，2025年上半年稳健医疗消费品业务毛利率达 到58.6%，同比提升1.7个百分点；营业利润率为14%，同比提升1.2个百分点。医疗板块盈利水平同步改 善，上半年稳健医疗从产品结构、新技术及新产品迭代、组织运营效率提升及渠道建设等各方面进行了 全面整合与提质提效，营业利润率提升至8.6%。 在经营业绩稳步提升的同时，稳健医疗持续强化股东回报，累计分红与回购超募资净额。根据2025年半 年报，公司将 ...

2025年8月22日，稳健医疗(300888.SZ)发布2025年半年度报告。截至2025年8月21日，共有39个机构投 资者披露持有稳健医疗A股股份，合计持股量达4.56亿股，占稳健医疗总股本的78.28%。其中，前十大 机构投资者包括稳健集团有限公司、中国银行股份有限公司-华宝中证医疗交易型开放式指数证券投资 基金、中国工商银行股份有限公司-易方达创业板交易型开放式指数证券投资基金、香港中央结算有限 公司、厦门乐源投资合伙企业(有限合伙)、中国农业银行股份有限公司-中证500交易型开放式指数证券 投资基金、国寿安保基金-中国人寿保险股份有限公司-分红险-国寿安保基金国寿股份均衡股票型组合单 一资产管理计划(可供出售)、国寿安保基金-中国人寿保险股份有限公司-分红险-国寿安保基金国寿股份 均衡股票型组合单一资产管理计划(可供出售)、中国人寿保险股份有限公司-传统-普通保险产品-005L- CT001沪、中国农业银行股份有限公司-交银施罗德内需增长一年持有期混合型证券投资基金，前十大 机构投资者合计持股比例达75.93%。相较于上一季度，前十大机构持股比例合计下跌了0.51个百分点。 外资态度来看，本期较上一 ...

Group 1 - The core viewpoint of the article emphasizes the innovative "Four Precision" work method adopted by the Henan Securities Regulatory Bureau to enhance the regular visits to listed companies, aiming to address their challenges and promote high-quality development in the capital market [3][5]. - As of the end of July 2025, the Henan Securities Regulatory Bureau has visited 46 listed companies, resolving 49 issues with a problem resolution rate of 87.5%, injecting new momentum into the high-quality development of the capital market in Henan [3][4]. - The bureau has implemented a "three batches" visiting mechanism, which includes visits led by provincial leaders, joint visits with local government departments, and independent visits by the bureau itself, creating a comprehensive service network for listed companies [3][4]. Group 2 - The bureau has focused on understanding the production and operational status of companies, particularly in light of complex economic conditions, by conducting targeted research on issues such as new productivity, expanding domestic demand, and the impact of tariffs [4][5]. - A problem-oriented approach has been adopted, establishing a work ledger to categorize and address the difficulties faced by companies, leading to the introduction of supportive policies for mergers and acquisitions, with 12 transactions involving over 30 billion yuan executed since 2025 [4][5]. - The regulatory services have been integrated with the visiting work, ensuring that regulatory requirements are communicated while providing professional guidance, resulting in significant actions such as the formulation of market value management systems and the implementation of share buyback policies [5]. Group 3 - The Hebei Securities Regulatory Bureau has also initiated a large-scale visit to listed companies, collaborating with various departments to enhance service quality and support enterprise development, achieving a coverage rate of 85% by visiting 70 companies and resolving 33 issues by the end of July 2025 [7][8]. - A "three-level linkage" mechanism has been established to facilitate collaboration among provincial, municipal, and district government departments, ensuring effective problem management through a closed-loop system [8][10]. - The bureau has emphasized the importance of integrating resources from regulatory, financial, and media sectors to provide tailored financial services and professional guidance to companies, thereby enhancing their operational capabilities [10][12]. Group 4 - The Jilin Securities Regulatory Bureau has been conducting regular visits to listed companies since 2024, focusing on understanding their operational challenges and promoting high-quality development in the capital market [15][18]. - The bureau has tailored its visiting plans based on the local industrial landscape and company needs, addressing issues related to incentive mechanisms, direct financing, and board responsibilities [16][18]. - Training sessions on mergers and acquisitions and other market tools have been organized to enhance the investment value of listed companies, with a noticeable increase in the activity of major asset restructuring in the region [17][18].

Group 1 - The stock price of Yingke Medical is reported at 35.66 yuan, down by 0.97 yuan, a decrease of 2.65% from the previous trading day [1] - The stock reached a high of 37.00 yuan and a low of 35.64 yuan during the trading session, with a total transaction volume of 574 million yuan [1] - The main business of Yingke Medical includes medical protection, rehabilitation care, and health therapy, with key products such as disposable gloves, wheelchairs, and hot/cold packs widely used in medical, consumer, and industrial sectors [1] Group 2 - On August 14, the net outflow of main funds was 117 million yuan, accounting for 0.7% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow reached 464 million yuan, representing 2.8% of the circulating market value [1]